{"id":1924,"date":"2024-03-14T11:01:51","date_gmt":"2024-03-14T11:01:51","guid":{"rendered":"https:\/\/www.merckconnect.com\/prevymis\/?page_id=1924"},"modified":"2026-04-07T14:44:01","modified_gmt":"2026-04-07T14:44:01","slug":"kidney-transplant-adverse-reactions","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/","title":{"rendered":"Adverse Events"},"content":{"rendered":"<link rel='stylesheet' id='vivid360-heading-css-css' href='https:\/\/www.merckconnect.com\/prevymis\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/heading\/css\/style.min.css?ver=1770880337' media='all' \/>\n\n<div class=\"vivid360-heading default-hcp-fontsize default-hcp-tablet-fontsize default-hcp-mobile-fontsize\" id=\"aa86f6576-2743-4bc5-a468-0472bce29c1a\"><h1 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h1FontSizeDesktop);--tabletFontSize:var(--h1FontSizeDesktop);--mobileFontSize:var(--h1FontSizeMobile);--desktopLineHeightSize:var(--h1LineHeightDesktop);--tabletLineHeightSize:var(--h1LineHeightDesktop);--mobileLineHeightSize:\" id=\"top\"><strong>Adverse events in kidney transplant patients<\/strong><\/h1><\/div>\n\n\n<link rel='stylesheet' id='vivid360-spacer-css-css' href='https:\/\/www.merckconnect.com\/prevymis\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/spacer\/css\/style.min.css?ver=1770880337' media='all' \/>\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<div class=\"vivid360-heading default-hcp-fontsize default-hcp-tablet-fontsize default-hcp-mobile-fontsize\" id=\"a5655d469-0738-4308-ad4b-d176c1b6b24f\"><h2 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h2FontSizeDesktop);--tabletFontSize:var(--h2FontSizeDesktop);--mobileFontSize:var(--h2FontSizeMobile);--desktopLineHeightSize:var(--h2LineHeightDesktop);--tabletLineHeightSize:var(--h2LineHeightDesktop);--mobileLineHeightSize:\" id=\"\">In a Phase 3 clinical trial in adult high-risk CMV D+\/R- kidney transplant recipients, <br><strong>prophylaxis with PREVYMIS<sup>\u00ae<\/sup> (letermovir) was generally well-tolerated<\/strong><\/h2><\/div>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<p><strong>Adverse events through Week 28 (~200 days) post-transplant in adults<\/strong><\/p>\n\n\n<link rel='stylesheet' id='vivid360-list-css-css' href='https:\/\/www.merckconnect.com\/prevymis\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/list\/css\/style.min.css?ver=1770880337' media='all' \/>\n\n<div class=\"vivid-block-list content-width  default-list block-d67dd1e3-17e2-4e07-ba99-a5f65bf52bd2\" data-image=\"\" data-image-mobile=\"\" data-image-all=\"\" data-image-all-mobile=\"\" data-icon-color=\"#333\" data-text-color=\"#333\" data-client-id=\"block-d67dd1e3-17e2-4e07-ba99-a5f65bf52bd2\"><ul class=\"first-level\"><li>Diarrhea was reported in at least 10% of subjects in the PREVYMIS group and at a frequency greater than valganciclovir (PREVYMIS 32% vs valganciclovir 29%)<\/li><\/ul><\/div>\n\n\n\n<p><strong>Fewer patients discontinued PREVYMIS vs valganciclovir due to an AE through Week 28 (~200 days) post-transplant<\/strong><\/p>\n\n\n\n<div class=\"vivid-block-list content-width  default-list block-40e5d10f-18fd-4973-a60c-bb1d0f801987\" data-image=\"\" data-image-mobile=\"\" data-image-all=\"\" data-image-all-mobile=\"\" data-icon-color=\"#333\" data-text-color=\"#333\" data-client-id=\"block-40e5d10f-18fd-4973-a60c-bb1d0f801987\"><ul class=\"first-level\"><li>4% of patients receiving PREVYMIS discontinued due to an AE vs 14% of patients receiving valganciclovir<\/li><li>Most frequently reported AEs leading to discontinuation were neutropenia (1% with PREVYMIS vs 2% with valganciclovir) and leukopenia (1% with PREVYMIS vs 5% with valganciclovir)<\/li><\/ul><\/div>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<div class=\"vivid360-heading\" id=\"a8047e8b2-b5c6-4705-9981-8fbe0237aa93\"><h3 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h3FontSizeDesktop);--tabletFontSize:var(--h3FontSizeDesktop);--mobileFontSize:var(--h3FontSizeMobile);--desktopLineHeightSize:var(--h3LineHeightDesktop);--tabletLineHeightSize:var(--h3LineHeightDesktop);--mobileLineHeightSize:\" id=\"\">In a Phase 3 clinical trial in adult high-risk CMV D+\/R- kidney transplant recipients,<br> <strong>Selected laboratory abnormalities through Week 28 (~200 days) post-transplant<\/strong><\/h3><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:16px;--mobile-spacer:16px;--tablet-spacer:16px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<figure class=\"wp-block-flexible-table-block-table is-content-justification-left is-scroll-on-mobile\"><table class=\"has-fixed-layout\" style=\"border-style:solid;border-width:0\"><tbody><tr><td style=\"background-color:#3f6075;border-width:2px;border-color:#5d5d5d;width:300px\"><\/td><td style=\"background-color:#3f6075;color:#FFF;text-align:center;vertical-align:middle;font-size:22px;line-height:1.5;border-width:2px 2px 2px 0;border-color:#5d5d5d;padding:15px;width:223px\"><strong>PREVYMIS (n=292)<\/strong><\/td><td style=\"background-color:#3f6075;border-style:solid;border-color:#5d5d5d;font-size:22px;color:#FFF;text-align:center;vertical-align:middle;line-height:1.5;border-width:2px 2px 2px 0;padding:15px;width:245px\"><strong>Valganciclovir (n=297)<\/strong><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;border-width:0 2px 2px;border-color:#5d5d5d;padding:18px 15px 18px 20px\"><strong>Absolute neutrophil count (cells\/\u03bcL)<\/strong><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d;padding:18px 15px\"><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d;padding:18px 15px\"><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;text-align:left;vertical-align:middle;border-width:0 2px 2px;border-color:#5d5d5d;padding:18px 15px 18px 48px\">&lt; 500<\/td><td style=\"font-size:22px;line-height:1.5;text-align:center;vertical-align:middle;border-width:0 2px 2px 0;border-color:#5d5d5d\">2%<\/td><td style=\"font-size:22px;line-height:1.5;text-align:center;vertical-align:middle;border-width:0 2px 2px 0;border-style:solid;border-color:#5d5d5d\">7%<\/td><\/tr><tr><td style=\"padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;font-size:22px;line-height:1.5;text-align:left;vertical-align:middle\">500 \u2212 &lt; 750<\/td><td style=\"font-size:22px;line-height:1.5;text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px\">1%<\/td><td style=\"padding:18px 15px;text-align:center;vertical-align:middle;font-size:22px;line-height:1.5;border-width:0 2px 2px 0;border-style:solid;border-color:#5d5d5d\">4%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">750 \u2212 &lt; 1000<\/td><td style=\"font-size:22px;line-height:1.4;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">1%<\/td><td style=\"font-size:22px;line-height:1.5;text-align:center;vertical-align:middle;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d\">8%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d\"><strong>Total &lt; 1000<\/strong><\/td><td style=\"padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;font-size:22px;line-height:1.5;text-align:center;vertical-align:middle\"><strong>5%<\/strong><\/td><td style=\"border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5;text-align:center;vertical-align:middle\"><strong>18%<\/strong><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Hemoglobin (g\/dL)<\/strong><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d\"><\/td><td style=\"border-color:#5d5d5d;border-width:0 2px 2px 0\"><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">&lt; 6.5<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">2%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">0%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">6.5 \u2212 &lt; 8.0<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">4%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">5%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">8.0 \u2212 &lt; 9.5<\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">29%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">32%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Total &lt; 9.5<\/strong><\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\"><strong>34%<\/strong><\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\"><strong>37%<\/strong><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Platelets (cells\/\u03bcL)<\/strong><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d\"><\/td><td style=\"border-color:#5d5d5d;border-width:0 2px 2px 0\"><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">&lt; 50000<\/td><td style=\"border-color:#5d5d5d;text-align:center;vertical-align:middle;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">0%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">0%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">50000 &#8211; &lt; 100000<\/td><td style=\"border-color:#5d5d5d;text-align:center;vertical-align:middle;border-width:0 2px 2px 0;padding:18px 15px 18px 17px;font-size:22px;line-height:1.5\">1%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">3%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Total &lt; 100000<\/strong><\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px 18px 16px;font-size:22px;line-height:1.5\"><strong>1%<\/strong><\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\"><strong>3%<\/strong><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Leukocytes (cells\/\u03bcL)<\/strong><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d\"><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d\"><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle;padding:18px 15px 18px 48px\">&lt; 1000<\/td><td style=\"border-color:#5d5d5d;text-align:center;vertical-align:middle;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">1%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">2%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\">1000 &#8211; &lt; 2000<\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">5%<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">19%<\/td><\/tr><tr><td style=\"text-align:left;vertical-align:middle;border-color:#5d5d5d;padding:18px 15px 18px 48px;font-size:22px;line-height:1.5;border-width:0 2px 2px\">2000 &#8211; &lt; 2500<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">4%<\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">14%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.4;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Total &lt; 2500<\/strong><\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px 18px 16px;font-size:22px;line-height:1.5\"><strong>10%<\/strong><\/td><td style=\"font-size:22px;line-height:1.3;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\"><strong>35%<\/strong><\/td><\/tr><tr><td style=\"border-color:#5d5d5d;text-align:left;vertical-align:top;border-width:0 2px 2px;padding:18px 15px 18px 20px;font-size:22px;line-height:1.5\"><strong>Serum creatinine (mg\/dL)<\/strong><\/td><td style=\"border-width:0 2px 2px 0;border-color:#5d5d5d\"><\/td><td style=\"border-color:#5d5d5d;border-width:0 2px 2px 0\"><\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 48px;border-width:0 2px 2px;border-color:#5d5d5d;text-align:left;vertical-align:middle\">&gt; 2.5<\/td><td style=\"vertical-align:middle;text-align:center;border-color:#5d5d5d;border-width:0 2px 2px 1px;padding:18px 15px;font-size:22px;line-height:1.5\">24%<\/td><td style=\"font-size:22px;line-height:1.4;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">22%<\/td><\/tr><tr><td style=\"text-align:left;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px;padding:18px 15px 18px 48px;font-size:22px;line-height:1.5\">&gt; 1.5 \u2212 2.5<\/td><td style=\"font-size:22px;line-height:1.5;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\">49%<\/td><td style=\"text-align:center;vertical-align:middle;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\">52%<\/td><\/tr><tr><td style=\"font-size:22px;line-height:1.5;padding:18px 15px 18px 20px;border-width:0 2px 2px;border-style:solid;border-color:#5d5d5d;text-align:left;vertical-align:middle\"><strong>Total &gt; 1.5<\/strong><\/td><td style=\"vertical-align:middle;text-align:center;border-color:#5d5d5d;border-width:0 2px 2px 0;padding:18px 15px;font-size:22px;line-height:1.5\"><strong>73%<\/strong><\/td><td style=\"font-size:22px;line-height:1.4;padding:18px 15px;border-width:0 2px 2px 0;border-color:#5d5d5d;text-align:center;vertical-align:middle\"><strong>73%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"background-color:transparent;height:16px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-16\"><\/div>\n\n\n\n<div class=\"vivid360-heading\" id=\"a1d8d8b76-cc8c-4469-9a10-54c2e08a3b23\"><h3 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h3FontSizeDesktop);--tabletFontSize:var(--h3FontSizeDesktop);--mobileFontSize:var(--h3FontSizeMobile);--desktopLineHeightSize:var(--h3LineHeightDesktop);--tabletLineHeightSize:var(--h3LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Prespecified analysis of neutropenia or leukopenia events through Week 28 in adults<sup>1<\/sup><\/strong><\/h3><\/div>\n\n\n\n<div class=\"vivid-block-list content-width  default-list block-c8d69107-eecb-49e4-9ee8-097bb5c00ed5\" data-image=\"\" data-image-mobile=\"\" data-image-all=\"\" data-image-all-mobile=\"\" data-icon-color=\"#333\" data-text-color=\"#333\" data-client-id=\"block-c8d69107-eecb-49e4-9ee8-097bb5c00ed5\"><ul class=\"first-level\"><li>The proportion of participants with events of leukopenia or neutropenia (reported as an AE by an investigator or as laboratory criteria defined in protocol as total WBC count &lt;3500 cells\/\u03bcL or ANC &lt;1000 cells\/\u03bcL) through Week 28 post-transplant was significantly lower in the PREVYMIS group compared with the valganciclovir group (26% vs 64%); <em>P<\/em>&lt;0.001<sup>1<\/sup><\/li><li><strong>Limitation: This analysis captures both clinical AEs reported by investigators and reported laboratory abnormalities. Laboratory abnormalities are not consistently reported as clinical AEs and laboratory results are generally considered to be more objective<\/strong><\/li><\/ul><\/div>\n\n\n\n<div style=\"background-color:transparent;height:16px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-16\"><\/div>\n\n\n\n<div class=\"vivid360-heading default-hcp-tablet-fontsize default-hcp-mobile-fontsize\" id=\"a5d5c6af4-d76c-4d90-a940-24ed375af276\"><h2 class=\"has-primary-color content-width fontWeightRegular\" style=\"--desktopFontSize:21px;--tabletFontSize:var(--h2FontSizeDesktop);--mobileFontSize:var(--h2FontSizeMobile);--desktopLineHeightSize:31.5px;--tabletLineHeightSize:var(--h2LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Pediatric information<\/strong><\/h2><\/div>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Use of PREVYMIS\u00ae (letermovir) in pediatric patients&nbsp;<\/strong><\/p>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<p>The use of PREVYMIS for prophylaxis of CMV disease in high-risk [D+\/R-] kidney transplant recipients 12 years of age and older and weighing at least <span class=\"no-wrap-text\">40 kg<\/span> is supported by evidence from an adequate and well-controlled study in adults and safety data from pediatric HSCT recipients (Trial P030). Letermovir exposures are expected to be similar between adult and pediatric patients 12 years of age and older and weighing at least <span class=\"no-wrap-text\">40 kg<\/span>.&nbsp;<\/p>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<p>The safety and effectiveness of PREVYMIS have not been established for kidney transplant recipients less than 12 years of age or weighing less than <span class=\"no-wrap-text\">40 kg<\/span>.<\/p>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<div class=\"wp-block-vivid360-button-parent btn-block-container content-width button-justify-left\"><link rel='stylesheet' id='vivid360-button-block-css-css' href='https:\/\/www.merckconnect.com\/prevymis\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/button\/css\/style.min.css?ver=1770880337' media='all' \/>\n<link rel='stylesheet' id='vivid360-button-parent-block-css-css' href='https:\/\/www.merckconnect.com\/prevymis\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/button-parent\/css\/style.min.css?ver=6.8.5' media='all' \/>\n\n<div class=\"vivid360-button-block fullWidth-mobile\"><a class=\"btn primary primary-regular\" role=\"button\" style=\"font-size:14px;letter-spacing:0.86px;border-radius:5px;border-style:solid;justify-content:center;text-align:center;width:100%\" href=\"\/prevymis\/kidney-transplant-pediatric\/\" title=\"P030 Study Design\" target=\"_self\" rel=\"noopener\" data-design-category=\"button\" data-design-label=\"P030 Study Design\" data-design-module=\"element\" data-event-name=\"element_click\">P030 Study Design<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"background-color:transparent;height:16px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-16\"><\/div>\n\n\n\n<div class=\"vivid360-heading\" id=\"a87e94fec-bcd7-4395-a8fd-5e2f1f97cccd\"><h3 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:18px;--tabletFontSize:var(--h3FontSizeDesktop);--mobileFontSize:var(--h3FontSizeMobile);--desktopLineHeightSize:27px;--tabletLineHeightSize:var(--h3LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Reference<\/strong><\/h3><\/div>\n\n\n\n<div class=\"vivid-block-list content-width  block-6fbca73b-6801-4e7c-bf91-daa8173129e6\" data-image=\"\" data-image-mobile=\"\" data-image-all=\"\" data-image-all-mobile=\"\" data-icon-color=\"#333\" data-text-color=\"#333\" data-client-id=\"block-6fbca73b-6801-4e7c-bf91-daa8173129e6\"><ol class=\"first-level default-order\"><li>Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. <em>JAMA.<\/em> 2023;e239106. doi:10.1001\/jama.2023.9106<\/li><\/ol><\/div>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<p><a href=\"#top\" aria-label=\"#\">Back to top<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adverse events through Week 28 (~200 days) post-transplant in adults Fewer patients discontinued PREVYMIS vs valganciclovir due to an AE through Week&#8230;<\/p>\n","protected":false},"author":699,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[270],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[281],"ga4_page_customer_journey_stage":[336],"ga4_page_customer_specialty":[361],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[576],"ga4_page_product":[599],"ga4_page_region":[910],"ga4_page_therapeuticarea":[],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-1924","page","type-page","status-publish"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adverse Reactions in Kidney Transplant Recipients Taking PREVYMIS\u00ae (letermovir)<\/title>\n<meta name=\"description\" content=\"Review the adverse reactions for PREVYMIS\u00ae (letermovir) in a clinical trial with kidney transplant patients who are at high risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adverse Reactions in Kidney Transplant Recipients Taking PREVYMIS\u00ae (letermovir)\" \/>\n<meta property=\"og:description\" content=\"Review the adverse reactions for PREVYMIS\u00ae (letermovir) in a clinical trial with kidney transplant patients who are at high risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/\" \/>\n<meta property=\"og:site_name\" content=\"prevymis\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T14:44:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adverse Reactions in Kidney Transplant Recipients Taking PREVYMIS\u00ae (letermovir)","description":"Review the adverse reactions for PREVYMIS\u00ae (letermovir) in a clinical trial with kidney transplant patients who are at high risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/","og_locale":"en_US","og_type":"article","og_title":"Adverse Reactions in Kidney Transplant Recipients Taking PREVYMIS\u00ae (letermovir)","og_description":"Review the adverse reactions for PREVYMIS\u00ae (letermovir) in a clinical trial with kidney transplant patients who are at high risk.","og_url":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/","og_site_name":"prevymis","article_modified_time":"2026-04-07T14:44:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/","url":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/","name":"Adverse Reactions in Kidney Transplant Recipients Taking PREVYMIS\u00ae (letermovir)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/prevymis\/#website"},"datePublished":"2024-03-14T11:01:51+00:00","dateModified":"2026-04-07T14:44:01+00:00","description":"Review the adverse reactions for PREVYMIS\u00ae (letermovir) in a clinical trial with kidney transplant patients who are at high risk.","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/prevymis\/kidney-transplant-adverse-reactions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/prevymis\/"},{"@type":"ListItem","position":2,"name":"Adverse Events"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/prevymis\/#website","url":"https:\/\/www.merckconnect.com\/prevymis\/","name":"prevymis","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/prevymis\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/pages\/1924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/users\/699"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/comments?post=1924"}],"version-history":[{"count":19,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/pages\/1924\/revisions"}],"predecessor-version":[{"id":2656,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/pages\/1924\/revisions\/2656"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/media?parent=1924"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_audience?post=1924"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_birn_id?post=1924"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_branding?post=1924"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_businessunit?post=1924"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_campaign?post=1924"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=1924"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=1924"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=1924"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_experience?post=1924"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_indication?post=1924"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_material_intent?post=1924"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_product?post=1924"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_region?post=1924"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=1924"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/user_role?post=1924"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/mhh-area-of-interest?post=1924"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/access?post=1924"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/prevymis\/wp-json\/wp\/v2\/user_status?post=1924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}